Hemab Therapeutics Holdings, Inc. (COAG)
39.40
-0.48
(-1.20%)
USD |
NASDAQ |
Sep 11, 16:00
39.47
+0.07
(+0.18%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.840B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 4.051 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0023 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded in 2020 and is headquartered in Cambridge, MA. |
| URL | http://www.hemab.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Nov. 16, 2026 (est.) |
| Last Earnings Release | Aug. 11, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded in 2020 and is headquartered in Cambridge, MA. |
| URL | http://www.hemab.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Nov. 16, 2026 (est.) |
| Last Earnings Release | Aug. 11, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |